Outlook Therapeutics (OTLK) Capital Expenditures (2015 - 2019)

Outlook Therapeutics (OTLK) has 5 years of Capital Expenditures data on file, last reported at -$610979.0 in Q3 2019.

• Capital Expenditures for Q3 2019 came in at -$610979.0, down 148.38% year-over-year; the trailing twelve-month figure through Sep 2019 was $437307.0 (down 84.28% YoY), and the FY2019 annual result was $437307.0, down 84.28% from the prior year.
• Capital Expenditures retreated to -$610979.0 in Q3 2019 per OTLK's latest filing, from $761717.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $3.5 million in Q2 2015 and troughed at -$610979.0 in Q3 2019.
• A 5-year average of $632910.3 and a median of $255809.5 in 2018 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2018 and 2019: Capital Expenditures soared 5165.95% in 2018, then plunged 148.38% in 2019.
• A 5-year view of Capital Expenditures shows it stood at $364242.0 in 2015, then slumped by 94.31% to $20711.0 in 2016, then surged by 5091.17% to $1.1 million in 2017, then slumped by 78.01% to $236433.0 in 2018, then sank by 358.42% to -$610979.0 in 2019.
• Business Quant data shows OTLK's Capital Expenditures at -$610979.0 in Q3 2019, $761717.0 in Q2 2019, and $50136.0 in Q1 2019.